Cara Therapeutics Stock Price. Everything You Need To Know About The Cara Therapeutics Stock!
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 106 full-time employees. The company went IPO on 2014-01-31. The firm is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus. The Company’s KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Its novel compound, difelikefalin, is a highly selective, primarily peripherally acting kappa opioid receptor (KOR) agonist. The firm is developing an oral formulation of difelikefalin and has Phase III programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease (NDD-CKD), and atopic dermatitis (AD). In addition, the Company has initiated a Phase II/III program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP).
Cara Therapeutics Stock Price. Everything You Need To Know About The Cara Therapeutics Stock! performance
- Employees 106
- Company HQ Stamford
- Website https://www.caratherapeutics.com/
- CARA Asset Type Common Stock
- CARA Market Capitalization 41.1M
- Earnings Per Share -2.19
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
If you’re a retail investor from Malaysia, Thailand, Indonesia, or Vietnam looking to invest in the stock market, Cara Therapeutics is a stock worth considering. As a content marketing expert at Zorion, an investment platform dedicated to providing investment insights and recommendations, we can help you make informed decisions about your investments. Cara Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapeutics to treat pruritus and chronic kidney disease-associated pruritus. With our platform, you can access resources and educational materials to further enhance your investment knowledge. Discover how to invest in Cara Therapeutics and seize the opportunity to grow your portfolio. Start investing today with Zorion!
